	US 11,718,661 B2
	Composition for the treatment of antibody deficiencies
Guy Gorochov, Paris (FR); Martin Larsen, Paris (FR); Delphine Sterlin, Paris (FR); and Jehane Fadlallah, Paris (FR)
Assigned to INSERM (Instut National de la Santé et de la Recherche Médicale), Paris (FR); Sorbonne Université, Paris (FR); and Assistance Publique-Hôpitaux de Paris (APHP), Paris (FR)
Appl. No. 17/288,013
Filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Paris (FR); Sorbonne Université, Paris (FR); and Assistance Publique-Hôpitaux de Paris (APHP), Paris (FR)
PCT Filed Oct. 29, 2019, PCT No. PCT/EP2019/079477 § 371(c)(1), (2) Date Apr. 23, 2021, PCT Pub. No. WO2020/089203, PCT Pub. Date May 7, 2020.
Claims priority of application No. 18306410 (EP), filed on Oct. 29, 2018.
Prior Publication US 2021/0395348 A1, Dec. 23, 2021
Int. Cl. C07K 16/12 (2006.01); A61P 37/04 (2006.01); A61P 1/00 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/1271 (2013.01) [A61K 9/0053 (2013.01); A61P 1/00 (2018.01); A61P 37/04 (2018.01); A61K 2039/505 (2013.01); A61K 2039/542 (2013.01); C07K 2317/33 (2013.01)]

4 Claims

1. A method of treating an antibody deficiency in a subject in need thereof, comprising

administering to the subject a composition comprising IgA (immunoglobulins A)

wherein the composition is administered orally,

wherein the composition contains at least two different monoclonal IgA that are cross-reactive and bind to multiple bacterial targets,

and wherein the antibody deficiency is

a primary antibody deficiency that is SIgAd (Selective IgA deficiency) or common variable immunodeficiency (CVID); or

a secondary antibody deficiency that is myeloma, Chronic Lymphocitic Leukemia (CLL), or an immune deficiency induced by a medical treatment.